title: HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
abstract: As proviral human immunodeficiency virus type 1 (HIV-1) DNA can replenish and revive viral infection upon activation, its detection might offer significant therapeutic information, complementing the input provided by plasma RNA determination in the follow-up of infected individuals. A selected group of acutely infected subjects was studied to verify both total and 2-long terminal repeat (2-LTR) DNA proviral load during the acute phase of infection and thereafter. Patients were divided in two sex- and age-matched groups: 19 naive individuals who did not receive antiretroviral therapy during the observation period and 20 subjects treated according to current guidelines. Total and 2-LTR HIV-1 DNA proviral load, in addition to RNA viral load and CD4 cell count, were determined in peripheral blood mononuclear cells (PBMC) at baseline, 6 and 12 months after the first sampling. Total and 2-LTR HIV-1 DNA proviral load exhibited no significant variation at any time in the naive patients (total HIV-1 DNA ranging from 896 + or - 731 to 715 + or - 673 copies/10(5) PBMC and 2-LTR HIV-1 DNA ranging from 94 + or - 105 to 65 + or - 44 copies/10(5) PBMC), whereas a significant reduction in both total HIV-1 DNA (ranging from 997 + or - 676 to 262 + or - 174 copies/10(5) PBMC) and 2-LTR HIV-1 DNA proviral load (ranging from 116 + or - 55 to 26 + or - 35 copies/10(5) PBMC) was detected in highly active antiretroviral therapy (HAART) patients, together with a CD4(+) T cell count increase and RNA load decrease. HAART negatively affects both the labile HIV burden and the integrated proviral DNA, at least in the initial period of successful treatment, suggesting that quantification of HIV-1 DNA proviral load may be an important parameter in monitoring HIV infection.
authors.affiliation: Department of Haematology and Oncologic Science, Microbiology Section, National Institute Biostructure and Biosystem (INBB), Rome, Italy. mariacarla.re@unibo.it
authors.forename: M C
authors.initials: MC
authors.lastname: Re
authors.forename: F
authors.initials: F
authors.lastname: Vitone
authors.forename: C
authors.initials: C
authors.lastname: Biagetti
authors.forename: P
authors.initials: P
authors.lastname: Schiavone
authors.forename: F
authors.initials: F
authors.lastname: Alessandrini
authors.forename: I
authors.initials: I
authors.lastname: Bon
authors.forename: E
authors.initials: E
authors.lastname: de Crignis
authors.forename: D
authors.initials: D
authors.lastname: Gibellini
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D004279:DNA, Viral / Q000097:blood*; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D008297:Male; D008875:Middle Aged; D011533:Proviruses / Q000235:genetics / Q000302:isolation & purification*; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load; D014773:Virology / Q000379:methods
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D012367:RNA, Viral